This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Infectious Diseases, Other  • Dermatology  • Bites and Stings  • Alert me on articles by topic

JAMA. 2004;291:2188.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2004;53:264-265

1 figure omitted

Cutaneous leishmaniasis (CL) is a sand fly–borne parasitic infection. Preliminary data about cases of CL in military personnel deployed to three countries (Afghanistan, Iraq, and Kuwait) in Southwest/Central Asia have been published previously.¹ During August 2002–February 2004, Department of Defense (DoD) staff identified 522 parasitologically confirmed cases of CL in military personnel. Leishmania major was the etiologic agent for all 176 cases for which species data, obtained by isoenzyme electrophoresis of cultured parasites, are available. This update focuses on the 361 cases (69% of 522) in patients whose demographic data were collected systematically under treatment protocols for therapy with the pentavalent antimonial compound sodium stibogluconate (Pentostam®; GlaxoSmithKline, United Kingdom) at Walter Reed Army Medical Center, District of Columbia.¹ U.S. health-care providers should consider CL in persons with persistent skin lesions who were deployed to Southwest/Central Asia or who were in other areas where leishmaniasis is . . . [Full Text of this Article]